<DOC>
	<DOCNO>NCT02113826</DOCNO>
	<brief_summary>Alveolar soft part sarcoma ( ASPS ) , rare subset STS ( &lt; 1 % ) harbor ( X ; 17 ) ( p11 ; q25 ) translocation produce resultant ASPL-TFE3 fusion protein . Due nature high expression angiogenic factor , sunitinib cediranib produce overall response rate 55 % 43 % , respectively . However , efficacy pazopanib unknown metastatic ASPS .</brief_summary>
	<brief_title>Pazopanib Metastatic Alveolar Soft Part Sarcoma</brief_title>
	<detailed_description>Pazopanib , multi-targeted anti-angiogenesis inhibitor significantly prolong progression-free survival ( PFS ) patient metastatic soft-tissue sarcoma ( STS ) failure anthracycline-based regimen ( pazopanib v placebo , 4.6 v 1.6 month , HR=0.31 , 95 % CI 0.24-0.40 ; P &lt; .0001 ) . Regarding sunitinib ( continuous daily dose 37.5mg ) , median duration 10 month , median OS PFS 19 month 17 month , respectively small retrospective study ( ASPS , N=9 ) . With regard cediranib , 6-month PFS 60 % . In addition , randomize phase II trial sunitinib v cediranib cross-over disease progression recently initiate ( NCT01391962 ) . However , efficacy pazopanib unknown metastatic ASPS .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Alveolar Soft Part</mesh_term>
	<criteria>Key Histologically confirm diagnosis alveolar soft part sarcoma harbor TFE3 fusion stage IV relapse Age ≥ 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Measurable lesion define RECIST v1.1 Chemonaïve prior chemotherapy Adequate organ function Prior malignancy Active CNS disease Highrisk gastrointestinal bleeding Significant cardiovascular disease Uncontrolled hypertension Bleeding diathesis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Pazopanib</keyword>
	<keyword>Alveolar soft part sarcoma</keyword>
</DOC>